Latest news releases from PR.com for Anavex Life Sciences Corp. http://www.pr.com/press-releases Wed, 03 Dec 2008 13:55:42 -0500 http://www.pr.com/images/logo_white.jpg http://www.pr.com/ 68 69 PR.com provides Free Press Release Distribution, & is a unique Directory of Businesses, Products, Services, & Jobs - in all industries. Find Full Company Profiles. © 2008 PR Worldwide, Inc. 60 http://www.pr.com/press-release/103375 Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. [PR.com - September 04, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/103375 http://www.pr.com/press-release/98273 Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). [PR.com - August 02, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/98273 http://www.pr.com/press-release/92542 Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity of amyloid (beta)25-35 peptide (A(beta)25-35) in mice. This peptide is used to mimic the neurodegenerative processes found in [PR.com - July 15, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/92542 http://www.pr.com/press-release/91184 Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and established pharmaceutical companies. He is currently serving as a financial consultant specializing in strategic planning and [PR.com - June 20, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/91184 http://www.pr.com/press-release/86575 Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug candidates in clinical development, as well as lifecycle optimization for their leading oncology treatments including Sutent. [PR.com - May 23, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/86575 http://www.pr.com/press-release/68910 Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. [PR.com - January 24, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/68910 http://www.pr.com/press-release/67828 ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. [PR.com - January 16, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/67828 http://www.pr.com/press-release/67824 Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. [PR.com - January 16, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/67824 http://www.pr.com/press-release/67832 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. [PR.com - January 16, 2008] Anavex Life Sciences Corp. http://www.pr.com/press-release/67832